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Introduction
Vesicle-mediated transport of intracellular proteins drives the for-
mation of actin-based membrane projections such as lamellipodia 
and filopodia and the secretion of extracellular matrix–modifying 
factors that facilitate angiogenesis and tumor cell invasion (1). Ves-
icle transport is regulated by the Golgi apparatus, which posttrans-
lationally modifies, sorts, and packages proteins into vesicles that 
bud from the Golgi and are transported along microtubules to spe-
cific intracellular locations (2). Vesicle budding is enhanced by F- 
actin–mediated tensile forces exerted on Golgi membranes through 
a Golgi phosphoprotein 3 (GOLPH3)/MYO18A bridge (3). GOLPH3 
is recruited to the Golgi by a PITPNC1/RAB1B–containing pro-
tein complex that binds to Golgi-enriched phosphatidylinositol-4- 
phosphate (4). High expression of GOLPH3 and PITPNC1 promotes 
metastasis in experimental models and predicts a shorter duration of 
survival in cancer patients (4). On the basis of these findings, a model 
has been proposed in which pro-metastatic vesicle trafficking is driv-
en by mechanical forces that promote Golgi dispersal (5).
In certain epithelial tumor types, the ability to shift revers-
ibly between epithelial and mesenchymal states is essential for 
metastasis (6). This reversible differentiation switch is regulated 
by mutual antagonism between transcription factors that promote 
epithelial-to-mesenchymal transition (EMT) (e.g., ZEB, SNAIL, 
and TWIST family members) and microRNAs (miRs) that target 
the EMT-activating transcription factors (e.g., miR-200 family 
members and miR-34a) (6). Epithelial cell polarization along an api-
co-basal axis causes Golgi vesicles to coalesce into compact ribbon 
structures that face the apical surface and direct vesicle trafficking 
toward apical and basolateral membrane compartments (7). During 
EMT, the Golgi is repositioned to direct vesicle trafficking toward 
the leading edge of the cell and facilitate the formation of promi-
gratory focal adhesions and cytoplasmic protrusions (8). Thus, the 
Golgi is a dynamic organelle that is capable of sustained vesicle 
trafficking when dispersed or compact. However, the way in which 
EMT-induced vesicular trafficking is regulated remains unclear.
Here, we addressed this question using lung adenocarcinoma 
cell lines isolated from mice that develop metastatic lung ade-
nocarcinoma from expression of K-rasG12D and p53R172H (hereaf-
ter termed KP cells); these cells have variable metastatic activity 
that is tightly linked to EMT status and the ZEB1/miR-200 axis 
(9, 10). Highly metastatic KP cells have mesenchymal properties 
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ly, we assessed Golgi compaction in flank tumors and orthotopic 
lung tumors generated by injection of 344SQ cells into syngene-
ic, immunocompetent mice. Coimmunofluorescence staining 
was performed on the tumors to quantify GM130 and vimentin 
levels, which are correlated with Golgi organelle compaction (12) 
and EMT, respectively. Vimentin and GM130 staining intensities 
were highest on the tumor periphery and decreased exponentially 
with increasing distance from the periphery, whereas cell density 
remained constant (Figure 1C and Supplemental Figure 6). Mea-
sured radially from the tumor periphery inward, vimentin and 
GM130 staining intensities were significantly correlated (Spear-
man’s rank correlation coefficients = 0.85 and 0.98 in the flank 
and orthotopic lung tumors, respectively). Thus, EMT led to the 
formation of compact Golgi organelles.
The formation of ribbon-linked cisternal stacks increas-
es the mobility of proteins within cisternae and facilitates the 
accurate location and function of enzymes that modify N- and 
O-linked oligosaccharides (13). To determine whether EMT is 
associated with improved ribbon linking and cisternal stack-
ing, we initially performed fluorescence recovery after photo-
bleaching (FRAP) assays using a GFP-tagged Golgi enzyme, 
N-acetylgalactosaminyltransferase (GalNAcT), which showed 
that recovery was significantly faster in mesenchymal 344SQ 
cells than it was in epithelial 393P cells (Figure 1, D and E, and 
Supplemental Video 2). To determine whether these cells differ 
with respect to cisternal stacking, we quantified cisternal num-
bers and lengths per stack, which were higher in 344SQ cells 
than they were in 393P cells (Figure 1F). Thus, EMT is associat-
ed with improved ribbon linking and cisternal stacking.
GOLPH3 levels were similar in KP cells with epithelial or mes-
enchymal features (Supplemental Figure 7A), suggesting that the 
EMT-driven Golgi compaction process was not mediated through 
changes in GOLPH3 expression. Microtubule acetylation facili-
tates Golgi ministack transport (14), and Į-tubulin acetylation is 
increased through an inhibitory interaction between paxillin and 
the Į-tubulin deacetylase HDAC6 (15). However, the amounts of 
acetylated Į-tubulin and paxillin were similar in KP cells with epi-
thelial or mesenchymal features (Supplemental Figure 7B), argu-
ing against microtubule acetylation as a mechanism by which KP 
cells regulate Golgi organelle integrity during EMT. In contrast, 
the levels of ZEB1, a critical driver of EMT and metastasis in KP 
cells (9–11, 16), were negatively correlated with Golgi areas in the 
KP cell line panel (Supplemental Figure 7C). Ectopic ZEB1 expres-
sion in epithelial lung cancer cells (393P, 307P, and HCC827) and 
and revert to an epithelial state and lose their metastatic activity 
following ectopic expression of the miR-200b/c/429 cluster; con-
versely, poorly metastatic KP cells have epithelial properties and 
undergo mesenchymal differentiation and gain metastatic activity 
following ectopic expression of the EMT-activating transcription 
factor ZEB1 (9, 10). The findings presented here support a model 
in which EMT drives metastasis through a Golgi compaction pro-
cess that is distinct from GOLPH3-dependent mechanical forces 
that promote metastasis through Golgi dispersal.
Results
EMT drives Golgi compaction. To determine whether Golgi struc-
tural features are regulated during EMT, we initially quantified 
Golgi organelle areas in a panel of KP cell lines and human lung 
and breast cancer cell lines classified previously as mesenchy-
mal or epithelial (10, 11). As measured from volume projections 
of cells stained with antibodies against the cis-Golgi marker 
GM130, Golgi organelle areas were correlated inversely with 
mesenchymal classification (Figure 1A and Supplemental Fig-
ure 1A; supplemental material available online with this arti-
cle; doi:10.1172/JCI88736DS1). Compared with mesenchymal 
344SQ cells, epithelial 393P cells had less compact Golgi organ-
elles that contained smaller and more numerous Golgi elements, 
indicative of Golgi element fragmentation (Figure 1B, Supple-
mental Figure 1B, and Supplemental Video 1). Additionally, Gol-
gi organelle areas were correlated inversely with migratory and 
metastatic activities in KP cell lines and human lung cancer cell 
lines (Supplemental Figures 2 and 3).
On the basis of these findings, we sought to determine wheth-
er EMT causes Golgi compaction. Indeed, treatment of 393P cells 
with TGF-ȕ, which induces KP cells to undergo a partial EMT 
(10), decreased Golgi organelle areas (Supplemental Figure 4A), 
whereas shRNA-mediated depletion of E-cadherin dispersed 
393P cells but had no detectable effect on Golgi organelle areas 
(Supplemental Figure 4, B and C), suggesting that the TGF-ȕ–
induced Golgi compaction was not simply due to a loss of cell-cell 
contact. Next, we measured Golgi areas in 344SQ cells and A549 
human lung cancer cells that were subjected to wound healing 
assays. Golgi structures were more compact at the wound edge, 
where cells typically undergo EMT before migrating into the 
wound (2), than they were in cells located away from the wound 
edge (Supplemental Figure 5A). Furthermore, Golgi organelles 
that faced lamellipodia were more compact than Golgi that were 
not positioned in that direction (Supplemental Figure 5B). Last-
Figure 1. EMT leads to the formation of compact Golgi with improved ribbon linking and cisternal stacking. (A) The scatter plot shows Golgi organelle 
areas normalized to nuclear areas in epithelial and mesenchymal KP cells. Each dot represents Golgi organelle area in a single cell. (B) Confocal micro-
graphs of Golgi (GM130, green) and nuclei (DAPI, magenta) in representative epithelial (393P) and mesenchymal (344SQ) KP cells. A compact Golgi struc-
ture is indicated (arrow). Scale bars: 3 ȝm. (C) Confocal micrographs of a flank tumor formed by subcutaneous injection of 344SQ cells into a syngeneic, 
immunocompetent mouse. Nuclei were counterstained with DAPI (blue) and merged with GM130 (green) and vimentin (red) in an overlaid image (right); 
the magnified images show compact and dispersed Golgi morphologies in areas of high and low vimentin, respectively. Scale bars: 30 ȝm. The scatter plot 
to the right of the images shows normalized fluorescence intensities of cells (dots) measured radially inward from the tumor periphery. The curve fits for 
vimentin, GM130, and DAPI (red, green, and blue lines, respectively) were obtained from nonlinear regression using a 1-phase exponential decay equation. 
(D) Pseudocolored images of the Golgi enzyme GalNAcT in 344SQ cells and 393P cells at indicated time points during FRAP assays. The bleached regions 
of interest are indicated by arrowheads, and intensity levels are indicated by a lookup table (LUT) bar. Scale bars: 3 ȝm. (E) The scatter plot shows the 
intensity recovery profile (%) after photobleaching (n = 20 cells per group). (F) Electron micrographs of representative cisternal stacks (arrows) in 393P cells 
(left) and 344SQ cells (right). Scale bar: 1 ȝm. Bar graphs show the mean numbers of cisternae per stack (left) and cisternal lengths (right). n ≥ 10 cells per 
group. P values indicated (2-tailed Student’s t test). Results were replicated (n ≥ 2 experiments).
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Figure 2. Ectopic ZEB1 expression increases Golgi compaction. (A) Confocal micrographs of Golgi (GM130, green) and nuclei (DAPI, magenta) in 393P cells 
stably transfected with empty (Vec) or ZEB1 expression vectors. Scale bars: 3 ȝm. Scatter plots show the normalized Golgi areas in 393P cells (left), 307P 
cells (middle), and HCC827 cells (right) stably transfected with ZEB1 or empty (Vec) expression vectors. Each dot represents values from a single cell. (B) 
Scatter plots show the average Golgi element numbers (left) and areas (right) in 393P cells stably transfected with ZEB1 or empty (Vec) expression vectors. 
Each dot represents values from a single cell. (C) Pseudocolored images of FRAP assays using the Golgi enzyme GalNAcT in 393P_vector cells (left) and 
393P_ZEB1 cells (right) at time points indicated to the left of each row. The bleached regions of interest are indicated by arrowheads, and intensity levels 
are indicated by LUT bar (right). Scale bars: 3 ȝm. (D) The scatter plot shows the intensity recovery profile (%) after photobleaching. n = 20 cells per group. 
(E) Electron micrographs of representative cisternal stacks (arrows) in 393P_vector cells (left) and 393P_ZEB1 cells (right). Scale bar: 1 ȝm. Bar graphs show 
the mean numbers of cisternae per stack (left) and cisternal lengths (right). n > 10 cells per group. P values were determined using 2-tailed Student’s t 
test. Results were replicated (n ≥ 2 experiments).
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transfected cells by ectopic PAQR11 expression (Supplemental 
Figure 8D). Ectopic PAQR11 expression in lung cancer cells with 
low endogenous PAQR11 levels (393P and H226) led to a reduc-
tion in Golgi organelle areas (Supplemental Figure 8E). Thus, 
PAQR11 is a critical mediator of ZEB1-induced Golgi compaction.
Directional trafficking of secretory vesicles mediates cellular 
shifts between apico-basal and front-rear axes of polarity (7, 8). 
To determine whether ZEB1 regulates vesicle trafficking through 
PAQR11, we initially performed vesicular stomatitis virus-G 
(VSV-G) assays and found that ectopic ZEB1 expression increased 
anterograde vesicle trafficking to the plasma membrane, which 
was sharply attenuated by PAQR11 depletion (Figure 4A). Next, we 
examined whether PAQR11 regulates the tethering of retrograde 
vesicles to Golgi membranes, an essential step in protein traffick-
ing within the Golgi (31). Golgi membranes were isolated from 
PAQR11-deficient and -replete HEK293 cells that stably express 
cyan fluorescent protein–tagged (CFP-tagged) ȕ-1,4-galactosyl-
transferase (GalT) and incubated with vesicles containing yel-
low fluorescent protein–tagged (YFP-tagged) GalT. In this assay, 
colocalization of Golgi and vesicle particles provides a measure 
of vesicle tethering efficiency (32). Vesicles colocalized less with 
PAQR11-deficient Golgi than they did with PAQR11-replete Golgi 
(Supplemental Figure 9A), suggesting that PAQR11 promotes ret-
rograde vesicle tethering to Golgi membranes. Lastly, we quanti-
fied the ability of PAQR11-deficient and -replete 344SQ cells to 
form lumenized spheres in 3D Matrigel, a measure of apico-basal 
polarization (10). PAQR11-deficient 344SQ cells formed struc-
tures with incomplete lumens and disorganized Golgi (Figure 4B 
and Supplemental Figure 9B), and lumen formation was restored 
by reconstitution with full-length but not N- or C-terminally trun-
cated PAQR11 that did not localize to the Golgi (Figure 4C and 
Supplemental Figure 9C). Thus, PAQR11 enables ZEB1-driven 
vesicle trafficking and apico-basal polarization.
To elucidate the way in which PAQR11 regulates Golgi com-
paction and vesicle trafficking, we identified proteins that bind to 
the PAQR11 scaffolding domain by performing pull-down assays 
on 344SQ cell extracts using PAQR11 amino acids 1–28 as bait. On 
the basis of a prediction algorithm (https://www.predictprotein.
org), this N-terminal motif projects into the cytoplasm (Supple-
mental Figure 10A) and may function as a scaffolding domain 
similarly to the N-terminus of PAQR3 (33). Protein-binding activ-
ity of the PAQR11 N-terminal peptide was greater than that of a 
control PAQR11 C-terminal peptide (Supplemental Figure 10B). 
Sequencing of the proteins bound to the N-terminal peptide 
revealed multiple regulators of Golgi compaction (e.g., DCTN1, 
DCTN2, and ARF1) and vesicular biogenesis and trafficking (e.g., 
COPA, COPB1, COPG1, KIF2A, KIFC1, KIF22, SEC24A, and 
ARF1) (Figure 5A and Supplemental Table 2). On the basis of these 
findings, we postulated that the scaffolding domain of PAQR11 
is essential for Golgi compaction and vesicle trafficking. To test 
this hypothesis, we reconstituted PAQR11-deficient 344SQ cells 
with full-length or N-terminally truncated PAQR11 expression 
constructs. PAQR11 mutants that lack amino acids 1–10 (ǻN10), 
1–20 (ǻN20), or 1–28 (ǻN28) did not localize in the Golgi (Supple-
mental Figure 10C). In contrast, a PAQR11 mutant that lacks ami-
no acids 1–5 (ǻN5) localized in the Golgi similarly to WT PAQR11 
(Supplemental Figure 10, C and D) but failed to rescue Golgi 
Madin Darby canine kidney (MDCK) cells led to a reduction in 
Golgi organelle areas (Figure 2A; Supplemental Figure 7, D and 
E; and Supplemental Video 3) and, in 393P cells, enhanced Gol-
gi element condensation (Figure 2B), Golgi ribbon linking (Figure 
2, C and D, and Supplemental Video 4), and cisternal stacking 
(Figure 2E). Conversely, shRNA-mediated depletion of ZEB1 in 
344SQ cells (Supplemental Figure 7F) led to Golgi element frag-
mentation (Supplemental Figure 7G) and decreased Golgi ribbon 
linking (Supplemental Figure 7H), but Golgi organelles remained 
compact (Supplemental Figure 7I), which may be related to residu-
al ZEB1 expression in the ZEB1 shRNA transfectants (Supplemen-
tal Figure 7F). These findings suggest that Golgi elements initially 
fuse and subsequently coalesce into a compact organelle through 
ZEB1-dependent mechanisms.
The Golgi scaffolding protein PAQR11 enables Golgi compaction. 
To identify candidate mediators of ZEB1-induced Golgi compac-
tion, we mined Affymetrix transcriptional profiles in Gene Expres-
sion Omnibus GSE61395 (17), which compares the transcriptomes 
of 393P cells stably transfected with ZEB1 or empty expression 
vectors. We found that the Gene Ontology database (http:// 
geneontology.org/) term “Golgi apparatus” was significantly 
enriched in genes that were upregulated, but not downregulated, 
by ZEB1 (data not shown). Of 33 upregulated genes classified as 
Golgi-related in both the Gene Ontology database and the Uni-
versal Protein database (http://www.uniprot.org/), 18 were con-
firmed to be upregulated (≥2-fold, 393P_ZEB1 versus 393P_vector) 
by quantitative reverse transcriptase PCR (qPCR) analysis (Figure 
3A and Supplemental Table 1). Proteins encoded by the genes 
are involved in diverse Golgi-related functions, including vesic-
ular trafficking (RAB38 and SYTL2) (18–20), endomannosidase 
activity (MANEA) (21, 22), G protein–coupled receptor activity 
(RGS20) (23), lipid transport (ABCA5) (24), and signal transduc-
tion (CNKSR2 and PAQR11) (25, 26).
A member of a family of progestin and adiponectin Q recep-
tors with 7-transmembrane domains (27, 28), PAQR11 (encoded 
by MMD) has no homology to known drivers of Golgi compaction 
such as the motor proteins that transport Golgi elements along 
microtubules (e.g., KIFs and dyneins) or the adhesive proteins 
that mediate Golgi cisternal stacking and ribbon linking (e.g., 
GRASP55 and GRASP65) (29, 30). Instead, PAQR11 functions as 
a scaffold for multiprotein complexes in the Golgi (27). We rea-
soned that, because Golgi compaction involves the recruitment 
and coordinated actions of multiple proteins, the scaffolding func-
tions of PAQR11 may mediate ZEB1-induced Golgi compaction. 
To address this possibility, we first confirmed that ectopic ZEB1 
expression increased PAQR11 protein levels in 393P cells (Supple-
mental Figure 8A). We then performed time-lapse microscopy on 
344SQ cells cotransfected with EGFP-tagged PAQR11 and red flu-
orescent protein–tagged GalNAcT, which confirmed that PAQR11 
is a dedicated Golgi protein (Supplemental Video 5). Next, we 
depleted PAQR11 in 344SQ cells, 393P_ZEB1 cells, and H1299 
human lung cancer cells by stable transfection of PAQR11 shRNAs 
(Supplemental Figure 8B) and found that PAQR11 deficiency led 
to Golgi organelle dispersal (Figure 3B), Golgi element fragmenta-
tion (Supplemental Figure 8C), and a loss of cisternal ribbon link-
ing (Figure 3, C and D, and Supplemental Video 6) and stacking 
(Figure 3E). Golgi compaction was restored in PAQR11 shRNA–
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element condensation (Figure 5B) and Golgi organelle compac-
tion (Figure 5C). Collectively, these findings suggest that the N- 
terminus of PAQR11 has Golgi localization and scaffolding func-
tions that regulate Golgi compaction and vesicle trafficking.
PAQR11 is a target of ZEB1-silenced miRs. The above findings 
warranted further studies to elucidate the way in which ZEB1 
upregulates PAQR11 expression. Given that ZEB1 functions pri-
marily as a transcriptional repressor (34), we postulated that ZEB1 
Figure 3. PAQR11 depletion impairs Golgi compaction. (A) The bar graph shows the results of qPCR analysis performed to validate Affymetrix profiles of 
Golgi-related genes in 393P_ZEB1 cells and 393P_vector cells (n = 3). Expression levels are relative to values in 393P_vector cells, which were set at 1.0. *P < 0.05; 
#P < 0.01; †P < 0.001. (B) Scatter plots show Golgi areas normalized to nuclear areas in 344SQ cells (left), 393P_ZEB1 cells (middle), and H1299 cells (right) stably 
transfected with 1 of 2 distinct PAQR11 shRNAs (shPAQR11#1 or shPAQR11#3) or scrambled control shRNA (shCTL). Each dot represents values from a single 
cell. (C) Pseudocolored images of the Golgi enzyme GalNAcT during FRAP assays on 344SQ cells stably expressing PAQR11 shRNA (shPAQR11, bottom panels) 
or scrambled shRNA (shCTL, top panels) at time points indicated under the images. The bleached regions of interest are indicated by arrowheads, and intensity 
levels are indicated by LUT bars (right). Scale bars: 3 ȝm. (D) The scatter plot shows the intensity recovery profile (%) after photobleaching. n ≥ 20 cells per group. 
(E) Electron micrographs of representative cisternal stacks (arrows) in 344SQ_shCTL cells (left) and 344SQ_shPAQR11 cells (right). Scale bar: 1 ȝm. Bar graphs 
show the mean numbers of cisternae per stack (left) and cisternal lengths (right). n = 10 cells per group. P values were determined using 2-tailed Student’s t test 
or ANOVA for comparisons between 2 groups or more than 2 groups, respectively. Results were replicated (n ≥ 2 experiments).
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upregulates PAQR11 by silencing miRs that target PAQR11. To test 
this hypothesis, we examined the PAQR11 3′-UTR and found that 
it has predicted binding sites for miR-200b/c, -148a, -206, and 
-182 (TargetScan, www.targetscan.org), the levels of which were 
correlated inversely with ZEB1 and PAQR11 levels in the KP cell 
line panel (Figure 6A and Supplemental Table 3). The activity of 
a PAQR11 3′-UTR reporter was repressed by ectopic miR-200b/c, 
-148a, or -206 but not -182 (Figure 6B), and miR-induced repres-
sion of PAQR11 3′-UTR reporter activity was relieved by muta-
genesis of the concordant miR binding sites (Figure 6C). Ectopic 
expression of each miR (Figure 6D) was sufficient to decrease the 
levels of PAQR11 mRNA (Figure 6E) and protein (Figure 6F) and 
Figure 4. PAQR11 depletion attenuates antero-
grade vesicle trafficking and impairs cell polariza-
tion. (A) Images of EGFP-VSV-G–transfected 393P_
vector cells (top row), 393P_ZEB1 cells (second row), 
and 393P_ZEB1 cells stably transfected with scram-
bled shRNA (shCTL, third row) or PAQR11 shRNA 
#1 (fourth row) or #3 (bottom row) after transfer 
to the permissive temperature. Total VSV-G was 
detected by measurement of EGFP signal intensity, 
and plasma membrane-bound (surface) VSV-G 
was detected by staining of nonpermeabilized cells 
with an anti–VSV-G antibody. Scale bars: 10 ȝm. 
The scatter plots display the ratio of surface VSV-G 
to total VSV-G in each cell (dots, n > 15 cells per 
group) for each condition. (B) Micrographs of 344SQ 
spheres grown in 3D Matrigel cultures. In bright-
field images (left), spheres with intact lumens (top) 
or defective lumens (bottom) are indicated with an 
arrow and shown at higher magnifications (insets). 
In confocal images (right), spheres with organized 
(top) or disorganized (bottom) Golgi alignment 
along lumen surfaces (boxed areas) are shown at 
higher magnifications (insets). Scale bars: 75 ȝm 
and 20 ȝm (insets). (C) Bright-field micrographs of 
344SQ spheres showing that lumen formation in 
PAQR11-deficient structures is rescued by reconsti-
tution with WT PAQR11 (PAQR11) but not truncated 
PAQR11 lacking N-terminal (ǻN) or C-terminal (ǻC) 
peptides. Scale bars: 40 ȝm. P values were deter-
mined using 2-tailed Student’s t test or ANOVA 
for comparisons between 2 groups or more than 2 
groups, respectively. Results were replicated (n ≥ 2 
experiments).
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(TRANSFAC; http://www.gene-regulation.com/pub/databases.
html). Mutagenesis of these sites increased Mir148a promoter activ-
ity in reporter assays (Figure 7C), and ZEB1 bound to these promot-
er elements in ChIP assays (Figure 7D), suggesting that miR-148a is 
a direct transcriptional target of ZEB1. Examination of the Mir206 
genomic locus revealed predicted binding sites for ZEB1 and GATA3 
within the miR-206 precursor. The activity of a reporter containing 
the miR-206 precursor was repressed by ectopic ZEB1 expression, 
and ZEB1-induced repression was relieved by mutagenesis of the 
predicted binding site for GATA3 but not ZEB1 (Figure 7E). In ChIP 
assays of the miR-206 precursor, binding activity was detected for 
GATA3 but not ZEB1 (Figure 7F), and shRNA-mediated depletion 
of GATA3 (Figure 7G), a miR-200 target that is highly expressed in 
KP cells (16), increased the expression of miR-206 but not miR-148a 
(Figure 7H), suggesting that GATA3 mediates ZEB1-induced sup-
pression of miR-206. Thus, ZEB1 silences miR-148a and miR-206 
through distinct mechanisms.
PAQR11 is essential for EMT-driven metastasis. Kaplan-Meier 
analysis showed that PAQR11 levels were prognostic for shorter sur-
vival durations in a compendium of 12 independent human lung ade-
nocarcinoma cohorts (Supplemental Table 4) and in a pan-cancer 
analysis of over 30 tumor types available through The Cancer 
Genome Atlas (Figure 8A). Furthermore, PAQR11 levels were cor-
related with the presence of an EMT-related gene expression sig-
nature (36) in compendia of human lung adenocarcinoma cohorts 
and breast adenocarcinoma cohorts (Supplemental Table 5). These 
findings led us to postulate that PAQR11 is required for EMT-driven 
metastasis. To test this hypothesis, we initially injected PAQR11- 
deficient and -replete 344SQ cells into syngeneic, immunocompe-
tent mice and found that the flank tumors generated were of similar 
size, but PAQR11-deficient tumors were markedly less metastatic 
(Figure 8B and Supplemental Figure 11A). Furthermore, intratho-
racic injection of PAQR11-replete or -deficient H1299 human lung 
cancer cells into nude mice showed that PAQR11 deficiency reduced 
orthotopic lung tumor size and the number of metastases to medias-
tinal lymph nodes and the contralateral lung (Supplemental Figure 
11B and data not shown). Conversely, compared with empty vector 
controls, 393P cells that have ectopic PAQR11 expression formed 
flank tumors that were larger and generated more lung metasta-
ses (Supplemental Figure 11, C and D). To determine how PAQR11 
enhances metastatic activity, we examined the effect of PAQR11 
deficiency on the in vitro properties of KP cells and human lung can-
cer cells. PAQR11 depletion reduced tumor cell migration in wound 
healing assays (Figure 8C and Supplemental Figure 12A) and at low 
density on plastic (Figure 8D and Supplemental Figure 12B). In colla-
gen gels, tumor cells formed spheroids that invaded collectively and 
as single cells that exhibited ameboid and mesenchymal morpholo-
gies (Supplemental Video 7), and PAQR11 depletion inhibited spher-
oid invasion (Figure 8E and Supplemental Figure 12C). PAQR11 
depletion decreased the migratory and invasive activities of tumor 
cells in Boyden chamber assays (Figure 8F and Supplemental Figure 
13). Reconstitution with WT but not ǻN5 mutant PAQR11 reversed 
the effects of PAQR11 shRNAs on cell migration and invasion in 
Boyden chambers (Supplemental Figure 14, A and B) and single-cell 
migration on plastic (Supplemental Figure 14, C–F). Conversely, 
ectopic PAQR11 expression increased the migration and invasion 
of 393P cells and H441 cells (Supplemental Figure 15). PAQR11- 
induce Golgi dispersal (Figure 6G), suggesting that PAQR11 is a 
functional target of miR-200c, miR-148a, and miR-206.
ZEB1 directly silences miR-200c (35), but whether miR-148a 
and miR-206 are transcriptional targets of ZEB1 is unclear. To 
address this question, we performed ZEB1 gain- and loss-of-function 
studies, which showed that all 3 miRs are silenced by ectopic ZEB1 
expression (Figure 7A) and upregulated by ZEB1 depletion (Figure 
7B). To determine how ZEB1 silences miR-148a, we examined the 
miR-148a promoter, which revealed 3 predicted ZEB1-binding sites 
Figure 5. PAQR11 has scaffolding functions required for Golgi compaction. 
(A) PAQR11-associated proteins identified by liquid chromatography– 
tandem mass spectrometry. Lines indicate known protein-protein interac-
tions as shown here by pull-down assays (present study) and as reported 
in Biological General Repository for Interaction Data sets (BioGRID), 
Biomolecular Interaction Network Database (BIND), and Human Protein 
Reference Database (HPRD). (B) Scatter plots show the average Golgi 
element number (left) and areas (right) in 344SQ_shPAQR11 cells stably 
transfected with vectors that express EGFP alone (shPAQR11_EGFP), WT 
PAQR11 (shPAQR11_EGFP-PAQR11), or mutant PAQR11 that lacks amino 
acids 1–5 (shPAQR11_EGFP-PAQR11ǻN5). Each dot represents values from 
a single cell. (C) The scatter plot shows Golgi areas normalized to nuclear 
areas in 344SQ_shPAQR11 cells stably transfected with vectors that express 
EGFP alone (shPAQR11_EGFP), WT PAQR11 (shPAQR11_EGFP-PAQR11), or 
mutant PAQR11 that lacks amino acids 1–5 (shPAQR11_EGFP-PAQR11ǻN5). 
Each dot represents values from a single cell. P values were determined 
using 2-tailed Student’s t test or ANOVA for comparisons between 2 groups 
or more than 2 groups, respectively. Results in B and C were replicated  
(n ≥ 2 experiments).
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Figure 6. PAQR11 is a target of multiple miRs. (A) Heat map of PAQR11, ZEB1, and miR levels in KP cells (n = 3 samples per cell) with legend (left).  
(B) The PAQR11 3ƍ-UTR and predicted miR binding sites are shown at top. Bar graphs show luciferase activities in 344SQ cells (left) and H1299 cells (right) 
transiently cotransfected with PAQR11 3ƍ-UTR reporter and negative control (NC) or gene-specific pre-miRs (n = 3 samples per condition). §P < 0.0001. 
(C) Illustrations of PAQR11 3ƍ-UTR reporters (top) showing the mutated miR-148a site (left), mutated miR-206 sites (middle), and mutated miR-200c sites 
(right). Bar graphs show luciferase activities in 344SQ cells transiently cotransfected with negative control (NC) or gene-specific pre-miRs and reporters 
that were empty (Vec) or contained WT PAQR11 3ƍ-UTR sequences or PAQR11 3ƍ-UTRs with mutations in either (MT1 or MT2) or both (MT1+2) of the predict-
ed binding sites. (D) The bar graph shows the results of qPCR analysis of ectopic miR-148a, -206, and -200c levels in 393P_ZEB1 cells stably transfected 
with vectors expressing ectopic miRs or with empty vectors (Vec). (E) The bar graph (n = 3 samples per condition) shows the results of qPCR analysis of 
PAQR11 mRNA levels in 393P_ZEB1 cells stably transfected with vectors expressing ectopic miRs or with empty vectors (Vec). (F) Western blot analysis 
of PAQR11 levels in 344SQ cells (top) and H1299 cells (bottom) transfected with pre-miRs or negative control (NC) oligos. ȕ-Actin was included as loading 
control. (G) The scatter plots show Golgi areas normalized to nuclear areas in 393P_ZEB1 cells (left), 344SQ cells (middle), and H1299 cells (right) that 
stably express ectopic miRs or empty vector (Vec). Each dot represents values from a single cell. P values were determined using 2-tailed Student’s t test 
or ANOVA for comparisons between 2 groups or more than 2 groups, respectively. Results were replicated (n ≥ 2 experiments). See complete unedited blots 
in the supplemental material.
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Figure 17A) or tumor cell proliferation in monolayer culture (Sup-
plemental Figure 17B). To determine whether the miRs that target 
PAQR11 suppress tumor cell metastatic properties, we performed 
miR gain- and loss-of-function studies in KP cells. Ectopic expres-
sion of miR-148 or miR-206 suppressed the metastasis, but not 
deficient 344SQ cells formed smaller but more numerous focal 
adhesions (Supplemental Figure 16A) and smaller lamellipodia 
(Supplemental Figure 16B), suggesting a defect in the matura-
tion of these structures. However, PAQR11 depletion had minimal 
effects on tumor cell colony formation in soft agar (Supplemental 
Figure 7. ZEB1 silences miR-206 and miR-148a through distinct mechanisms. (A) qPCR analysis of miR levels expressed as a ratio (ZEB1/Vec), with 
307P_vector set at 1.0. (B) The bar graph shows qPCR analysis of miR levels in 344SQ cells stably transfected with ZEB1 shRNAs (#1 or #2) or scram-
bled control shRNA (shCTL). Results expressed as a ratio (shZEB1/shCTL), with 344SQ_shCTL set at 1.0. (C) Reporter activities in 393P cells transiently 
transfected with Mir148a promoter reporters containing WT (blue) or mutated (white) E-boxes. (D) miR-148a chromatin immunoprecipitation assays 
on chromatin immunoprecipitated with anti-ZEB1 or IgG antibodies. PCR amplification of E1/E2 locus (148a-E1+2) or E3 locus (148a-E3) on the Mir148a 
promoter. Results expressed as a ratio of qPCR values (anti-ZEB1/IgG). Mir200b/c/429 locus (200b-E) and the miR-148a precursor (pre-148a) were included 
as positive and negative controls, respectively. Arrows indicate locations of PCR primers. (E) Reporter activities in 393P_vector cells (Vec) and 393P_ZEB1 
cells (ZEB1) transiently transfected with miR-206 promoter reporters containing intact (blue or red) or mutated (white) miR binding sites. (F) miR-206 ChIP 
assays. Chromatin was immunoprecipitated with anti-ZEB1 (ZEB1), anti-GATA3 (GATA3), or IgG antibodies. PCR amplification of sites within the miR-206 
precursor (pre-206) or a negative control region in the miR-206 promoter (1k). Arrows indicate locations of PCR primers. (G) qPCR analysis of GATA3 levels 
in 344SQ cells stably transfected with GATA3 shRNA (shGATA3#1 or shGATA3#2) or scrambled shRNA (shCTL). Results are expressed as a ratio (shGATA3/
shCTL), with shCTL set at 1.0. (H) qPCR analysis of miR-148a levels and miR-206 levels. Results are expressed as a ratio (shGATA3/shCTL), with shCTL set 
at 1.0. Unless otherwise indicated, results represent the averages of triplicate samples per condition. P values determined using 2-tailed Student’s t test or 
ANOVA for comparisons between 2 groups or more than 2 groups, respectively. Results were replicated (n ≥ 2 experiments).
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Figure 8. High PAQR11 levels enhance lung 
adenocarcinoma metastatic properties. (A) 
Kaplan-Meier plots of compendia of lung adeno-
carcinoma cohorts (left) and over 30 tumor types 
(right). The groups with highest (“top third”), 
lowest (“bottom third”), and intermediate (“mid-
dle third”) PAQR11 mRNA levels were compared. 
Numbers of patients alive at each time point 
indicated under graphs. P values determined 
by univariate Cox and stratified log-rank test 
correcting for cancer type. (B) Scatter plots of 
primary tumor weights (left) and lung metasta-
sis numbers (right) per mouse (dots). (C) Bright-
field micrographs of cells at the leading edges 
of scratch-wounded cultures of 393P_ZEB1 cells 
stably transfected with scrambled control shRNA 
(shCTL) or PAQR11 shRNA (shPAQR11). Bar graph 
shows percent wound closure 24 and 48 hours 
after placing of wounds. (D) Time-lapse tracing 
of movements of 344SQ cells stably transfected 
with scrambled control shRNA (shCTL) or PAQR11 
shRNA (shPAQR11). Movements of individual 
cells over 6 hours indicated by colored lines  
(n = 15 cells per group). Bar graphs show quan-
tification of cell speed (left) and directionality 
(right). (E) Bright-field micrograph of a 393P_
ZEB1 spheroid in collagen showing cells invading 
singly (red arrow) or collectively (white arrow). 
Scale bar: 100 ȝm. The bar and whisker plot 
shows quantification of single-cell (single) and 
collective invasions (n > 20 spheroids per group). 
(F) Bright-field micrographs of migrated and 
invaded cells in Boyden chambers. 393P_ZEB1 
cells stably transfected with scrambled control 
shRNA (shCTL) or 1 of 2 distinct PAQR11 shRNAs 
(shPAQR11#1 or shPAQR11#3) stained with crys-
tal violet (purple). Scale bar: 200 ȝm. Bar graph 
shows quantification of migrated and invaded 
cells. Unless otherwise indicated, results repre-
sent averages of triplicate samples per condition. 
P values were determined using 2-tailed Stu-
dent’s t test or ANOVA for comparisons between 
2 groups or more than 2 groups, respectively. 
Results were replicated (n ≥ 2 experiments).
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Treatment of cells with brefeldin A and other inducers of Gol-
gi stress such as golgicide A or Exo1 leads to Golgi fragmentation, 
inhibition of endoplasmic reticulum–Golgi transport, and imped-
ance of protein secretion (43). Golgi fragmentation is a patholog-
ical feature of infection with Chlamydia trachomatis and Shigella 
flexneri and several neurodegenerative diseases, including amy-
otrophic lateral sclerosis, Alzheimer’s, Parkinson’s, and spinocer-
ebellar ataxia type 2 (43–47). Golgi fragmentation by Golgi stress 
inducers has been largely ascribed to the inhibition of ARF small 
G protein–guanine nucleotide exchange factor (GEF) complexes 
(43). ARF4 levels are upregulated by the CREB3 transcription fac-
tor following exposure to Golgi stress inducers, and ARF4 deple-
tion confers resistance to stress-induced Golgi fragmentation (43). 
Thus, the Golgi actively senses stress stimuli and relays a signal to 
the nucleus to induce factors critical for the reestablishment of Gol-
gi homeostasis in a manner akin to the unfolded protein response, 
a transcriptional program that maintains homeostasis in the endo-
plasmic reticulum following disturbances in cellular redox regu-
lation or aberrantly high protein production (48). Whether Golgi 
stress response pathways also maintain Golgi integrity by upregu-
lating PAQR11 levels through transcriptional programs like the one 
described here remains to be determined.
In one working hypothesis, tumor cells undergo EMT to 
disseminate from the primary site and revert to an epithelial 
state in the metastatic niche in order to colonize and proliferate 
(49, 50). The findings presented here raise the possibility that 
differentiation state plasticity requires transcriptional control 
of Golgi functions. However, lineage tracing studies in breast 
cancer models showed that metastatic tumor cells exhibit no 
evidence of having undergone EMT (51), and conditional dele-
tion of transcriptional activators of EMT in pancreatic cancer 
models had no effect on metastasis (52), raising the possibility 
that EMT is entirely dispensable for metastasis or is relevant 
to metastasis in limited tumor types or specific mutational 
contexts. As shown here and elsewhere (53), metastatic tumor 
cells have the capacity to invade through collective or ameboid 
migratory modes, which may constitute a default pathway fol-
lowing genetic inactivation of EMT or a preferred pathway in 
certain tumor types or mutational contexts.
Inhibiting short- and long-range cellular migratory activities 
has the potential to suppress tumor growth and metastasis (54). 
Small-molecule inhibitors of kinesin motor proteins that control 
post-Golgi trafficking suppress tumor cell motility and inhibit 
mitosis in a broad spectrum of solid tumor types (55). The findings 
presented here highlight the potential utility of targeting process-
es in the Golgi to prevent metastasis in cancer patients.
Methods
See Supplemental Methods for full details.
Quantification of Golgi organelle area and Golgi element size and 
number. The area occupied by GM130-stained structures was quanti-
fied in volume projections with a limiting polygon. As described previ-
ously (56), the Golgi area was divided by the nucleus area in the same 
cell to generate a normalized area fraction (n = 50–70 cells per group). 
Cells were chosen randomly for such measurements. Golgi element 
size and number were determined from maximum intensity projec-
tions of deconvolved, thresholded (Otsu), and watershed-segmented 
the size, of 344SQ flank tumors in syngeneic, immunocompetent 
mice (Supplemental Figure 18A) and the migration and invasion of 
393P_ZEB1 cells and 344SQ cells in Boyden chambers (Supplemen-
tal Figure 18, B and C), whereas antagomirs to miR-148a or miR-206 
enhanced the migration and invasion of 393P cells (Supplemental 
Figure 18D). Collectively, these findings suggest that PAQR11 is a 
mediator of EMT-driven lung adenocarcinoma cell motility, inva-
sion, and metastasis.
Discussion
Genome-wide copy number analyses and gain-of-function 
screens established GOLPH3 as an oncogene that is commonly 
targeted for amplification in human cancer (37). GOLPH3 bridg-
es phosphatidylinositol-4-phosphate and actomyosin and thereby 
drives Golgi dispersal and vesicular budding (3, 38). A PITPNC1/
RAB1B protein complex anchors GOLPH3 to the Golgi, facilitating 
Golgi extension and the release of secretory vesicles containing 
factors that promote extracellular matrix remodeling and tumor 
angiogenesis (4). Collectively, these findings support a model in 
which pro-metastatic vesicular trafficking is driven by mechanical 
forces that promote Golgi dispersal.
In contrast to the GOLPH3-dependent mechanism by which 
metastasis occurs through Golgi dispersal, the findings pre-
sented here support an alternative model in which metastasis 
occurs through a Golgi compaction process that is accompanied 
by enhanced ribbon linking, cisternal stacking, and post-Golgi 
vesicular transport. This is analogous to the Golgi compaction 
and polarization observed in cells that undergo EMT and migrate 
directionally in wound healing assays (39, 40), implying that 
the pro-metastatic Golgi compaction process is part of a normal 
wound healing response that is co-opted by metastatic tumor cells 
in order to gain migratory and invasive properties.
The formation of ribbon-linked cisternal stacks is driv-
en by several factors, including retrograde vesicle trafficking, 
which requires the tethering of retrograde vesicles to the Golgi 
by tethering factors such as the conserved oligomeric Golgi 
complex (COG), golgins (e.g., GM130 and GOLGIN-45), and 
the adhesive proteins GRASP55 and GRASP65 (29). During 
Drosophila spermatogenesis, COG and the Golgi-associated 
retrograde protein complex promote ribbon formation in the 
acroblast (41), and COG is essential for tethering activity in the 
cell-free vesicle tethering assay used here (32), implying that 
PAQR11 could well be acting as a scaffold in retrograde vesicle 
tethering, which in turn may be needed for ribbon formation. 
Additionally, both GRASP55 and GRASP65 are phosphorylat-
ed by ERK, a RAS-activated kinase, and mutation of the ERK 
phosphorylation sites on GRASP55 enhances cisternal stack-
ing, indicating that ERK negatively regulates GRASP55 activi-
ty (42). PAQR11 recruits RAS proteins (H-, N-, and K-RAS) and 
RasGRP1 to the Golgi and is required for RAS-dependent ERK 
phosphorylation (25), arguing against RAS as a mediator of 
PAQR11-induced Golgi compaction. Instead, the findings pre-
sented here suggest that PAQR11 enables Golgi compaction by 
enhancing retrovesicle tethering to Golgi membranes and asso-
ciating with multiple regulators of Golgi compaction and vesi-
cle transport, scaffolding functions not previously attributed to 
PAQR11 or other PAQR family members.
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ing equation: (intA – bkgA)/(intB – bkgB) × MF, where intR, intA, 
and intB are the intensities of the ratio image, first-channel images, 
and second-channel images, respectively, bkgA and bkgB are the 
background values of the corresponding images, and MF is an arbi-
trary multiplication factor. Pseudocolored images were generated 
by a custom gradient lookup table. For visualization purposes, the 
pseudocolored images were intensity-calibrated.
Cell-free assays of intra–Golgi vesicle tethering. Cell-free assays were 
performed as described (32). Briefly, cell pellets were resuspended in 
4 times the pellet volume (1.5–2 ml) using 0.25 M sucrose, 10 mM 
HEPES pH 7.4, and lysed with 25 strokes in a tight-fitting Dounce 
homogenizer before floating of Golgi membranes following addition 
of 2.3 M sucrose and overlaying of the sample with 1.2 M and 0.8 M 
sucrose solutions buffered with HEPES. Golgi membranes collect-
ed from the 1.2 M/0.8 M interface were immunoblotted for the myc 
tag present in the GalT-CFP reporter construct to ensure that equal 
amounts of Golgi were used for each sample. Assay mixes containing 
a standard amount of GalT-YFP vesicles, HEK293 cytosol, and ener-
gy regeneration system were incubated for 40 minutes either at 37°C 
or on ice, then imaged using epifluorescence, acquiring 13–16 imag-
es per temperature for each sample. Images were processed using 
ImageJ as described previously (65), and the percentage of colocaliz-
ing Golgi and vesicle particles was determined. The ratio of observed 
colocalizations at 37°C versus 0°C in each sample was normalized to a 
measurement done on the same day using Golgi membranes isolated 
from control and PAQR11-deficient HEK293 cells and was presented 
as an average of 4–5 experiments ± SEM.
Microscopy. Confocal imaging was performed on a TCS-SP8 plat-
form (Leica Microsystems) equipped with ×63/1.4 NA oil, ×63/1.2 NA 
water, or ×40/1.2 NA oil objectives; 405/488/561/633 nm laser lines; 
and photomultiplier and hybrid (Leica HyD) detector systems. High- 
resolution images were acquired as described elsewhere (57, 66). For 
faster time-lapse imaging, an 8K resonant scanner was used. For some 
live cell imaging experiments, an Ultraview spinning disc module 
(PerkinElmer) or a Nikon Eclipse Ti live cell imaging microscope was 
used. Wide-field fluorescence, bright-field, and phase-contrast imaging 
were performed on an IX71 microscope (Olympus). Images were sub-
jected to iterative deconvolution (Huygens Professional, Scientific Vol-
ume Imaging) and processed using ImageJ. Background was subtracted 
using a rolling ball radius of 50–90 pixels. Colocalization analysis (Huy-
gens Professional) was plotted using Manders’ coefficients expressed as 
the percentage of red pixels that overlap with green pixels. Particle anal-
ysis routines (ImageJ) were used to measure focal adhesion parameters. 
Size of lamellipodia was estimated by selection of cortactin-stained 
lamellar structures using a free-hand selection macro (ImageJ).
Live and fixed cell imaging. Live cells were imaged in HEPES- 
buffered media within a cage incubator (Okolab). Golgi and PAQR11 
time-lapse images were acquired at intervals of 2 minutes. Nuclei were 
counterstained with DRAQ5.
For fixed cell imaging, cells were fixed using 4% paraformaldehyde 
for 10 minutes, permeabilized using 0.1% Triton X-100 for 10 minutes, 
and blocked with 3% BSA for 30 minutes. F-actin was detected using 
Alexa Fluor–conjugated phalloidin. Primary antibody incubation was 
performed in 3% BSA for 1 hour at room temperature or overnight at 4°C, 
followed by Alexa Fluor–conjugated secondary antibodies (1:500) in 3% 
BSA for 1 hour at room temperature. Nuclei were detected with DAPI in 
cells on coverslips mounted in ProLong Gold Antifade mounting medi-
3D stacks (n > 50 cells per group) by particle analysis (ImageJ, NIH; 
https://imagej.nih.gov/ij/).
FRAP assays. FRAP experiments were carried out as described 
previously (57, 58), with some modifications. Recovery was calculat-
ed within a circular region of interest (ROI) 1 ȝm in diameter. Twenty 
prebleach images were acquired and averaged to estimate prebleach 
intensity. The laser power was set to cause greater than 70% bleach 
depth within 3 or 4 iterations. The first phase of post-bleach images 
were acquired at the highest speed to record the fast recovery (diffu-
sion component) phase, and then 60–90 images were acquired at 1- 
and 10-second intervals to record the slow recovery (binding compo-
nent) phase. Time stacks were aligned by rigid body transformation 
and bleach-corrected using the average intensity from unbleached 
control cells. Recovery was calculated by the following equation: 
    (Equation 1)
where F
s
, F
b
, F
c
, and F
c0
 represent the fluorescent intensities of the 
bleach ROI, background, control ROI before photobleaching, and 
control ROI after photobleaching, respectively. F was expressed 
as the percentage of initial intensity. The data (n ≥ 20 cells from 4 
independent experiments) were averaged (mean values ± SEM) and, 
by nonlinear regression, fitted to the 1-phase exponential equation 
Y = Y0 + (plateau – Y0) × (1 – exp(–K × x)), where Y0 is the Y value 
when X (time) is 0. The plateau is the Y value at infinite times, and 
K is the rate constant expressed in the reciprocal of seconds. The 
mobile fraction was given by the plateau, and the recovery half-time 
was computed as T
1/2
 = ln(2)/K.
Golgi cisternal stack quantification. Electron microscopy was per-
formed as previously described (59, 60). Sections of 60 nm were 
mounted on Formvar-coated nickel grids and double contrasted with 
2% uranyl acetate for 5 minutes and 3% lead citrate for 5 minutes. 
Grids were imaged using a Philips transmission electron microscope.
For analysis, Golgi stacks were identified using morphological cri-
teria and quantified using standard stereological techniques (59, 60). 
Golgi images were captured at ×11,000 magnification. The longest 
cisterna was measured as the cisternal length of a Golgi stack using the 
ruler tool in Photoshop CS6. At least 20 cells were quantified in each 
experiment, and the results represent 2 independent experiments.
VSV-G transport. The EGFP-VSV-G (ts045) plasmid (Addgene 
11912) was a gift from Jennifer Lippincott-Schwartz (Janelia, How-
ard Hughes Medical Institute, Ashburn, Virginia, USA). As described 
previously (61), cells were transiently transfected with EGFP-VSV-G 
(ts045), transferred to the restrictive temperature of 40°C for 20 
hours, and then transferred to the permissive temperature of 32°C 
for 1 hour, at which point the cells were fixed. In nonpermeabilized 
cells, exofacial and total VSV-G was detected by staining with an 
anti–VSV-G antibody and by measurement of EGFP signal intensi-
ty, respectively. Fluorescence intensity was quantified as described 
previously (62), and ratio images (exofacial to total) were generated 
using a modified version of methods described previously (63). The 
individual image channels were registered by rigid body transfor-
mation with a stack registration plugin (64). A total of 12–20 imag-
es per group were smoothed using a median filter and thresholded 
(Otsu). Pixel-by-pixel ratio images were generated using the follow-
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ing data sets for 11 previously reported human lung adenocarcinoma 
cohorts (n = 1,492 tumors) (7), with the addition of another data set 
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Chitale data sets (n = 88 patients) were first removed from the Shed-
den data set, and one patient from Bild data set thought to poten-
tially represent SQCC was also removed (leaving n = 1,586 tumors 
in total). For the pan-cancer analysis, we collected expression data 
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